Question Bank › Small company, disproportionate current wins

Small company, disproportionate current wins

Small company, disproportionate current wins: the period's actual events are big relative to the enterprise

Calls Tested
499
Answered YES
12
Hit Rate
2.4%
rare by design

Akebia Therapeutics, Inc. (AKBA) — this company's answers

NO on the Q3 2021 call 2021-11-09 C+
The model's full reasoning — Q3 2021 call → NOWe need to determine if management describes specific business events that actually occurred in or around the recent period, that are large relative to the company's size, and that have contributed only partially to reported results with most effect still ahead. The events must be real, already-occurred, and management must convey the disproportion. Looking at the transcript: The main event is the potential approval of vadadustat, but that is contingent on FDA approval, which is not yet occurred. The PDUFA date is March 29, 2022, which is in the future. So that's not an actual event that occurred. The company is preparing for launch, but approval is not yet. So that's contingent. Other events: The MAA submission to EMA occurred last month (October 2021). That is a real event. But is it large relative to the company's size? The company is a biotech with a commercial product Auryxia. The MAA submission is a regulatory milestone, but it's not a revenue-generating event. It's a step toward approval. The company says they are eligible for milestones upon approval, but that's contingent. The MAA submission itself is not a large business event like a contract or order. The company also mentions the expansion of the UT Health study beyond 400 patients. That is a clinical trial expansion, not a business event. The company mentions the Vifor distribution agreement, but that was already in place. They talk about it as a key part of launch, but it's not a new event. The company mentions the settlement with generics for Auryxia, but that's about IP, not a new event. The company's revenue from Auryxia grew 7% in the quarter, but that's ordinary. The key thing is that the company is preparing for a potential launch of vadadustat, but that is contingent on FDA approval. The transcript explicitly says "vadadustat is not yet approved." So any events related to that are not actual business events that have occurred. The MAA submission is a real event, but it's a regulatory submission, not a business event like a contract or order. It's part of the pipeline.

← Back to the full AKBA analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe SPECIFIC BUSINESS EVENTS THAT ACTUALLY OCCURRED IN OR AROUND THE RECENT PERIOD — such as contracts or orders won, customers or programs signed, volumes shipped, facilities or offerings gone live, or commitments received — that are LARGE RELATIVE TO THE COMPANY'S OWN CURRENT SIZE, with management itself conveying the disproportion (for example by calling them the largest or most significant of their kind for this company, comparing them to the scale of the existing business, or describing how the company must now stretch, expand, or reorganize to handle them), AND does management indicate that these events have contributed only partially to the reported results, with most of their effect still ahead? Answer YES when management's own words convey this ONE phenomenon, in whatever form fits the industry: real, already-occurred events out of proportion to a still-small enterprise, narrated by operators now working to absorb them, so the reported numbers describe the company before the events land. One dominant event or several together both count, so long as the disproportion is management's own framing grounded in the specific events rather than in market-size claims. Answer NO if the events described are the company's ordinary rhythm of wins at its usual scale. NO if the 'big' items are pipeline, bids, negotiations, letters of intent, market opportunity, or anything contingent on approvals, financing, or decisions not yet made. NO if the events are already substantially delivered and reflected in the reported results. NO if the company is large or diversified enough that the events would not visibly change its scale. NO if management attributes the events chiefly to one-time conditions it expects to reverse. NO if the disproportion appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
NBTX Nanobiotix S.A. Q2 2023 2023-09-27 D
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
BFI BurgerFi International, Inc. Q3 2021 2021-11-12 C
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
ARAY Accuray Incorporated Q4 2016 2016-08-17 B
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

LIND · Q2 2017 → YESThe question is about whether management describes specific business events that actually occurred recently, that are large relative to the company's size, with most of their effect still ahead. YES The transcript shows management describing the recent launch of the National Geographic Quest (first guests July 29, just after quarter-end) as a major milestone: "the next leg of that growth strategy is now firmly underway," "the most advanced passenger ship built in the U.S. in decades," and "we are now on the precipice of delivering on the investment thesis from 2015.
GVP · Q1 2023 → YESThe question is about whether management describes specific business events that actually occurred, large relative to the company's size, with most effect still ahead. YES The transcript shows management describing specific, already-awarded contracts and orders ($19.1 million in new awards, including a $28 million five-year renewal with U.S. government labs) that are framed as the highest in nearly three years and the highest backlog in over a year.
GOGO · Q1 2016 → YESThe question is about whether management describes specific business events that actually occurred, large relative to the company's size, with most effect still ahead. YES The transcript shows management describing the 2Ku awards exceeding 1000 aircraft as a major milestone that has taken flight, with the company now needing to accelerate deployment, increase production rates, and potentially secure additional capital to absorb the scale.

More from the question bank

Tone of discovery: management sounds newly sRepeat pull from proven relationships plus rThe bottleneck is inside and being paid awaySelling something whose payoff to the buyer External validators convergingVolume records through a still-fixed gateAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.